207 related articles for article (PubMed ID: 32558236)
1. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
Matsushita T; Mangles S
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
Giangrande P; Abdul Karim F; Nemes L; You CW; Landorph A; Geybels MS; Curry N
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
6. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).
Klamroth R; Hampton K; Saulyte Trakymienė S; Korsholm L; Carcao M
Patient Prefer Adherence; 2021; 15():2443-2454. PubMed ID: 34764641
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
8. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
[TBL] [Abstract][Full Text] [Related]
9. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
[TBL] [Abstract][Full Text] [Related]
10. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct
Bjørnsdottir I; Støvring B; Søeborg T; Jacobsen H; Sternebring O
Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
[TBL] [Abstract][Full Text] [Related]
11. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
12. Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct
Møss J; Clausen WHO; Ezban M
Haemophilia; 2021 May; 27(3):e389-e392. PubMed ID: 33314455
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
[TBL] [Abstract][Full Text] [Related]
14. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
18. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT
Ezban M; Hansen M; Kjalke M
Haemophilia; 2020 Jan; 26(1):156-163. PubMed ID: 31809565
[TBL] [Abstract][Full Text] [Related]
19. Half-life extended factor VIII for the treatment of hemophilia A.
Tiede A
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]